pipette
ENEnglish

Clonal hematopoiesis and cytopenias following CAR19 therapy

Mark P. Hamilton, Nick A. Phillips, Troy Noordenbos, Jan Boegeholz, Takeshi Sugio, Brian J. Sworder, Stefan Alig, Zinaida Good, Joseph G. Schroers‐Martin, John Tamaresis, Mohammad Shahrokh Esfahani, Ying Lü, Mari Olsen, Chih Long Liu, Zach Ehlinger, Moksha Desai, Lori S. Muffly, RS Negrin, Sally Arai, Laura Johnston, Robert Lowsky, Everett Meyer, Andrew Rezvani, Judith A. Shizuru, Wen-Kai Weng, Parveen Shiraz, Surbhi Sidana, Sushma Bharadwaj, Melody M. Smith, Saurabh Dahiya, Bita Sahaf, Matthew Joshua Frank, Crystal Lee Mackall, Maximilian Diehn, David Matthew Kurtz, David Matthew Kurtz, Ash A. Alizadeh

Revista con revisión por paresUso en el mundo real

En palabras de los autores

CD19-directed chimeric antigen receptor T-cell therapy (CAR19) improves survival in patients with relapsed/refractory large B-cell lymphoma (rrLBCL) compared to immunochemotherapy with intent for autologous hematopoietic cell transplantation (HCT). However, major toxicities of CAR19 therapy include prolonged cytopenias, infection, and secondary hematologic malignancies. To investigate the mechanisms underlying these toxicities we studied a cohort of lymphoma patients receiving CAR19. CAR19-treated patients exhibited impaired immune reconstitution and increased infection compared to propensity-matched HCT-treated controls. Bone marrow analysis revealed prolonged post-CAR cytopenias is associated with clonal cytopenias of undetermined significance (CCUS) and is characterized by interferon-mediated inflammation. Despite durable lymphoma remissions, clonal hematopoiesis (CH) commonly expanded following CAR19 infusion and was associated with impaired immune reconstitution and the development of treatment related myeloid malignancy (tMN). The molecular composition and clinical outcomes of post-CAR tMN were comparable to those of post-HCT tMN. Single-cell DNA analysis revealed that most post-CAR CH clones harbored a single independent mutation and that CAR integration into T cells with CH mutations may drive persistence. These findings broadly implicate CH mutation burden and CH expansion in the development of post-CAR cytopenias and malignancies as well as mechanistically suggest these expansions occur in a background of marrow inflammation. Together, our results provide insight into the origins of key CAR19-associated toxicities, including infection and tMN.

Resultado principalEl resumen no menciona limitaciones.

Apareció: miércoles, 4 de noviembre. Nature Genetics. Revista con revisión por pares.

DOI: 10.1038/s41588-026-02795-5